Horizon Therapeutics announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply.
This short-term disruption is a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that have dramatically restricted capacity available for the production of TEPEZZA at its drug product contract manufacturer. In order to increase capacity for vaccine production, Operation Warp Speed has mandated the cancelation of previously contracted TEPEZZA drug product manufacturing space in December, which were required to maintain TEPEZZA supply. Without this manufacturing space, TEPEZZA production will be disrupted.
For complete details, please visit TEPEZZA Short-Term Supply Disruption FAQ
